Skip to main content
Equibles
VIR logo

VIR · Vir Biotechnology, Inc. · Metrics

Track VIR — free

Use VIR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VIR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.78 +0.21 (+1.82%) Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.99B
Shares
169.22M
Volume · Oct 28 954.39K Avg daily vol (3M) 1.91M

VIR metrics

94 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$11.57
Market cap
$1.99B

Price action

20 metrics
Price change (1W)
+7.7%
Price change (30D)
+10.1%
Price change (3M)
+30.7%
Price change (6M)
+12.5%
Price change (YTD)
+91.9%
Price change (1Y)
+86.9%
Trailing year
Price change (5Y)
-70.4%
52-week high
$11.78
52-week low
$5.12
Change from 52-week high
-1.8%
Change from 52-week low
+126.0%
Annualized volatility
64.7%
Annualized volatility (3M)
50.7%
Beta
1.8
RSI (14D)
59.1
Price vs SMA 50
+7.0%
Price vs SMA 200
+22.5%
Avg volume (3M)
1.91M
Relative volume
1.0
Average dollar volume
$20.12M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
169.22M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4.5×
reciprocal yield 22.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
6.2×
reciprocal yield 16.1%
P / book
1.9
reciprocal yield 52.2%
FCF yield
-10.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-13.4%

Historical valuation

8 metrics
P / E historical average (3Y)
3.6×
reciprocal yield 27.9%
P / E historical average (5Y)
3.6×
reciprocal yield 27.9%
EV / revenue historical average (3Y)
4.8×
reciprocal yield 21.0%
EV / revenue historical average (5Y)
4.8×
reciprocal yield 20.8%
EV / EBIT historical average (3Y)
2.0×
reciprocal yield 50.0%
EV / EBIT historical average (5Y)
2.0×
reciprocal yield 50.0%
EV / EBITDA historical average (3Y)
2.0×
reciprocal yield 50.5%
EV / EBITDA historical average (5Y)
2.0×
reciprocal yield 50.5%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
100.0%
Operating margin
-92.4%
Trailing 12 months
Net margin
-83.0%
Gross profit (TTM)
$303.21M
Operating profit (TTM)
−$280.19M
Net income (TTM)
−$251.68M
Trailing 12 months
Diluted EPS (TTM)
$-1.86
FCF margin
-67.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.88
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.06
EBITDA per diluted share (TTM)
$-1.98
Net income per diluted share (TTM)
$-1.86
Operating cash flow per diluted share (TTM)
$-1.56
Free cash flow per diluted share (TTM)
$-1.57
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$3.27
Stock compensation per diluted share (TTM)
$0.32
Book value per share
$5.49

Growth

11 metrics
Revenue growth YoY
+19,582.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$303.23M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+22.0%
Year over year · more shares
Revenue CAGR (3Y)
-65.1%
Revenue CAGR (5Y)
-2.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-25.6%
Return on assets
-20.7%
Debt / equity
0.0
Current ratio
6.0
EBITDA (TTM)
−$268.68M
Free cash flow (TTM)
−$203.59M
Quick ratio
6.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$528.59M
Latest balance sheet
Cash & equivalents
$278.73M
Total assets
$1.21B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$202.51M
Capital expenditures (TTM)
$1.09M
R&D (TTM)
$484.02M
SG&A (TTM)
$99.38M
Stock compensation (TTM)
$47.04M
R&D / revenue
159.6%
Stock compensation / revenue
15.5%

Ownership (13F)

9 metrics
13F filers
240
13F filer change QoQ
-16
Institutional ownership
86.9%
Conviction holders (share of 13F filers)
2.5%
Crowding (high-turnover and private-fund holders)
33.5%
Private-fund adviser ownership
30.7%
Active holders' share change QoQ
-0.2%
Holder tenure
11.5
Price vs estimated holder cost
+20.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
24.3%

Short interest

3 metrics
Short interest
9.6%
Latest settlement · 6.9 days to cover
Days to cover
6.9d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1706431 CUSIP 92764N102 13F (30d) 43 filings 43 filers Visit website Investor relations